Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some pharmacologic/safety mechanisms and adverse effects (CNS depression, sedation/hypnosis/anesthesia at therapeutic doses, respiratory depression, additive CNS depression with alcohol/other depressants, hypotension) are supported by the provided label excerpts, but many specific claims are unsupported/absent and several key high-risk labeling areas (boxed warnings, contraindications, full indications, detailed dosing/administration, and some interaction specifics) cannot be fully verified from the excerpt set.
Category Scores
Accurate Statements
Pentobarbital sodium is a barbiturate medication.
DESCRIPTION: "NEMBUTAL Sodium is a short-acting barbiturate"
Pentobarbital sodium is a central nervous system depressant.
DESCRIPTION: "The barbiturates are nonselective central nervous system depressants"
Pentobarbital sodium can cause sedation, hypnosis, and anesthesia at appropriate doses.
CLINICAL PHARMACOLOGY: "Barbiturates are capable of producing... mild sedation, to hypnosis, and deep coma."; "In high enough therapeutic doses, barbiturates induce anesthesia."; "produce drowsiness, sedation, and hypnosis."
Pentobarbital sodium is the salt form of pentobarbital.
DESCRIPTION: "The sodium salts of ... pentobarbital..."; "NEMBUTAL Sodium ... chemically designated as sodium ... barbiturate"
Pentobarbital sodium enhances the effect of GABA.
Unsupported Statements
Pentobarbital sodium is used in medical settings where rapid sedation and sleep are needed.
The provided label excerpts do not contain an indication statement using the concepts "rapid sedation" or "sleep" tied to pentobarbital sodium.
Pentobarbital sodium can be used for specialized indications under clinician supervision.
No provided label excerpt includes an indication list or statement about "specialized indications" or supervision for pentobarbital sodium.
Pentobarbital sodium enhances the effect of GABA.
No provided label excerpt supports a GABA-potentiation mechanism for pentobarbital.
Enhancing GABA slows brain activity.
No provided label excerpt supports this mechanism/causal statement.
The sodium salt is used to control formulation and dosing in injectable products.
The provided label excerpts describe composition/formulation but do not state that the sodium salt is used to control formulation/dosing rationale.
Whether a specific product is classified as controlled can vary by country and jurisdiction.
The provided label excerpts do not discuss cross-jurisdiction variation in controlled classification.
Common serious risks of pentobarbital include excessive sedation.
Although somnolence is listed and CNS depression is described, the excerpts do not explicitly frame this as a labeled "common serious" risk for pentobarbital.
Combining pentobarbital with other depressants can increase risk of overdose.
The excerpts describe additive CNS depressant effects and fatal overdosage generally, but do not explicitly state that combinations increase overdose risk.
Combining pentobarbital with other depressants can increase risk of overdose when combined with alcohol, opioids, benzodiazepines, and some sleep or anxiety medicines.
The provided label excerpts mention additive effects with alcohol/other CNS depressants but do not list opioids, benzodiazepines, or specific sleep/anxiety medicines, nor explicitly connect these combinations to overdose risk.
Clinicians typically adjust or avoid combinations of pentobarbital with other depressants.
The excerpts support additive CNS depressant effects and general cautions/avoidance in specific contexts, but do not state that clinicians "typically" adjust or avoid such combinations.
Contradictions
Important Omissions
Boxed warnings and full warnings/precautions coverage (including whether a boxed warning exists) cannot be audited because no boxed-warning text is included in the provided excerpt set.
Importance:
High
Contraindications section cannot be fully evaluated for pentobarbital sodium specifically because the claim list does not include contraindication-related statements, and only barbiturates (class) contraindications are provided as general text without linking to this product beyond excerpt scope.
Importance:
Moderate
Dosage and administration instructions (individualization, rate of administration, route-specific cautions, dosing regimens) are not evaluated because the provided excerpts do not include pentobarbital-sodium-specific dosing/regimen details beyond general barbiturate guidance.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several mechanistic and interaction/overdose-risk claims are unsupported or not verifiable from the provided excerpts; additionally, key high-risk labeling areas (boxed warnings, detailed dosing/administration) are not fully auditable from the excerpt set.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Many specific claims (indication/rapid sedation, GABA mechanism, detailed interaction and overdose-risk phrasing, and 'typical clinician adjustment/avoidance') are not supported by the provided label excerpts, and boxed-warning/detailed dosing content is not fully auditable.
Suggested Improvement
Restrict claims to text directly supported by the provided label sections (e.g., CNS depression, sedation/hypnosis/anesthesia at therapeutic doses, respiratory depression/apnea, additive CNS depressant effects with alcohol/other depressants, and listed adverse reactions like somnolence/hypotension/hypoventilation). Avoid unsupported mechanistic claims (GABA potentiation) and avoid specificity (opioids/benzodiazepines/sleep-anxiety meds; combination-to-overdose risk; 'common serious risks' framing; 'clinicians typically adjust/avoid').